In addition, new genes have been associated with a clinical phenotype of MODY with low penetrance, such as RFX6 (tested in our panel), a transcription factor involved in the maturation and function of the β-cell (56, 57), and NKX6-1, also involved in the development of β-cells (58). Here, RFX6 is linked to MODY.